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Abstract
Gastric adenocarcinoma is the second leading cause of cancer death worldwide. Epstein-Barr virus 
(EBV) is present in the malignant cells of approximately 10% of cases. It is unclear whether EBV 
is being missed in some gastric adenocarcinomas due to insensitive test methods or partial EBV 
genome loss. In the current study, we screened 113 gastric adenocarcinomas from low and high 
incidence regions (United States and Central America) for the presence of EBV using a battery 
quantitative real-time PCR (Q-PCR) assays targeting disparate segments of the EBV genome 
(BamH1W, EBNA1, LMP1, LMP2, BZLF1, EBER1) and histochemical stains targeting EBV-
encoded RNA (EBER), the latent proteins LMP1 and LMP2, and the lytic proteins BMRF1 and 
BZLF1. EBV DNA was detected by Q-PCR in 48/75 United States cancers (64%) and in 38/38 
Central American cancers (100%), which was a significant differrence. EBER was localized to 
malignant epithelial cells in 8/48 (17%) United States and 3/38 (8%) Central American cancers. 
Viral loads were considerably higher for EBER-positive versus EBER-negative cancers (mean 
162,986 versus 62 EBV DNA copies per 100,000 cells). A viral load of 2,000 copies per 100,000 
cells is recommended as the threshold distinguishing EBER-positive from EBER-negative tumors. 
One infected cancer selectively failed to amplify the LMP2 gene because of a point mutation, 
while another cancer had an atypical pattern of Q-PCR positivity suggesting deletion of large 
segments of the EBV genome. Three different viral latency profiles were observed in the cancers 
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based on constant expression of EBER and focal or variable expression of LMP1 or LMP2, 
without lytic protein expression. We conclude that EBV DNA levels generally reflect EBER 
status, and a panel of at least two Q-PCR assays is recommended for sensitive identification of 
infected cancers.
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Gastric cancer represents the fourth most common type of cancer and the second leading 
cause of cancer death worldwide.(1) The incidence of gastric cancer varies up to ten fold by 
geographic region, suggesting that genetic or environmental factors influence carcinogenesis 
and that different carcinogenesis models may be operative.(2) Patients often present with 
advanced and incurable disease. Even with resection and chemotherapy, high rates of 
recurrence result in poor overall survival, especially in developing countries. For unclear 
reasons, the incidence of gastric cancer in the proximal one-third of the stomach, where 
Helicobacter pylori (H. pylori) infection is less frequent, has been increasing worldwide.(2, 
3) Interestingly, Epstein-Barr virus (EBV) is more frequently identified in these proximal 
cancers.(4-8)
Patients who are at high risk of treatment failure are candidates for novel or aggressive 
treatment regimens. One promising therapeutic target is EBV, a ubiquitous gamma 
herpesvirus that has been implicated in the pathogenesis of a variety of benign and 
malignant diseases.(9, 10) EBV DNA is present in the malignant epithelial cells of about 
10% of gastric adenocarcinomas across geographic regions. The gastric adenocarcinomas 
most likely to be EBV-related are those of the “diffuse” histologic subtype with abundant 
infiltrating lymphocytes, poor to moderate differentiation, and those involving the proximal 
stomach.(4, 5, 7, 11-13) EBV association is also noted in cancers of the gastric stump 
following surgery, especially with Billroth II reconstruction after gastrectomy for benign 
gastroduodenal disease.(7, 14-17)
The gold standard assay for EBV targets EBV-encoded RNA (EBER) by in situ 
hybridization in paraffin-embedded tissue sections.(10, 18) This assay detects the most 
abundant latent viral transcripts and also localizes the viral infection to malignant cells by 
microscopy. However, the sensitivity of EBER staining has been called into question by 
investigators who have shown, by molecular or immunohistochemical assays, that EBV is 
present in some EBER-negative tumors.(19-25) Therefore, it is unclear whether EBV is 
being missed in some gastric adenocarcinomas due to insensitive testing methods or partial 
EBV genome loss.
Reliable diagnosis of EBV-related malignancy requires not only detection of the viral 
genome or its gene products, but also localization of the virus to the malignant cell fraction. 
Viral LMP2 and EBNA1 are target analytes since they are often expressed in EBV-related 
gastric cancers and they can be localized to tumor cells by immunohistochemistry,(10, 26, 
27) although EBNA1 histochemical stains are less reliable due to crossreactivity with a 
human protein.(28) LMP1 is rarely expressed, and the restricted pattern of viral gene 
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expression categorizes gastric cancers as latency type I, although latency types II, III and 
lytic infection have also been described.(12, 29-33)
To detect EBV at the DNA level, semiquantitative PCR has been used to screen gastric 
adenocarcinoma tissues for presence of the EBV genome and to demonstrate that high viral 
load correlates with EBER localization to malignant cells.(34) Modern real-time PCR 
methods now permit even more precise measurement of EBV viral load in DNA extracted 
from tissue specimens.(10)
Using a battery of tests for EBV DNA, RNA and protein, we examined 113 gastric 
adenocarcinomas from high and low incidence regions. This included 75 from the United 
States and 38 from Western Honduras. Western Honduras has been characterized as a region 
of high gastric cancer incidence, with standardized annual incidence rates of approximately 
39 cases per 100,000 for males and 21 per 100,000 for females.(35) In addition, endemic H. 
pylori infection has been confirmed in the region (85%). By comparison, the United States 
has a standardized annual incidence of 11 per 100,000 males and 6 per 100,000 females, 
with a lifetime risk of nearly 1%. To detect EBV in cancer tissues, we used a battery of 
sensitive and specific quantitative real-time PCR (Q-PCR) assays targeting six disparate 
regions of the EBV genome (BamH1W, EBNA1, LMP1, LMP2, EZLF1, EBER1). The virus 
was localized using EBER in situ hybridization and immunohistochemical assays targeting 
selected viral proteins expressed during latent infection (LMP1, LMP2A) or during active 
viral replication (BZLF1, BMRF1).
Materials and Methods
Gastric Adenocarcinoma Samples
Formalin fixed, paraffin-embedded blocks representing 113 gastric adenocarcinomas were 
obtained from UNC Hospitals tissue archives in Chapel Hill, NC (n=55), Massachusetts 
General Hospital in Boston, MA (n=20) and Western Regional Hospital, Santa Rosa de 
Copan, Honduras, Central America (n=38). The gastric adenocarcinomas obtained from 
Massachusetts General Hospital were selectively enriched for gastric stump site, with 16/20 
of these being stump cancers. The remaining cancers from all three sites were serial cases.
Clinical information included age, anatomic site of the cancer within the stomach, and, for 
the Central American cases, H. pylori serologic status. H. pylori serology was not performed 
on the gastric cancer patients from the United States, rather histologic evidence was sought 
for infection by bacteria consistent with H. pylori, but evidence was found in only one US 
case. Note that the sensitivity of microscopic detection of H.pylori is low given that surface 
mucosa was sometimes not even present in the cancer specimen used for this study. 
Furthermore, there is loss of H. pylori colonization as cancer develops.(1) For each cancer, 
histologic subtype was classified as intestinal versus diffuse using a modern version of 
Lauren’s criteria.(36) Paraffin sections were placed on coated glass slides for histochemical 
stains, or placed in a microfuge tube for manual DNA extraction as previously described in 
Ryan et al.(37)
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A battery of Q-PCR assays targeting six disparate regions of the EBV genome was used to 
measure EBV DNA. We previously validated five of these Q-PCR assays targeting 
BamH1W, EBNA1, LMP1, LMP2, and BZLF1 regions of the EBV genome(37), while the 
sixth assay targeting EBER1 was developed by Ling et al.(38) A Q-PCR assay targeting the 
human APOB gene was used, as previously described, to control for efficacy of DNA 
extraction and to normalize for the number of cells amplified per reaction.(37)
PCR was performed and products were detected on ABI Prism 7900 and 7500 Real-Time 
PCR instruments with Sequence Detection System software (Applied Biosystems, Foster 
City, CA). Thermocycling conditions were: 50°C for 2 minutes, 95°C for 10 minutes, and 
then 95°C for 15 seconds and 60°C for 1 minute for 40 cycles. Each 25μl reaction contained: 
1X TaqMan Universal Master Mix and TaqMan probe (10ρmol). Forward and reverse 
primers (15ρmol each) were used for all assays except those targeting LMP1 and BZLF1 in 
which 30ρmol was used. DNA template volume was 1μl, and failed APOB reactions were 
repeated at higher or lower template volumes. A standard curve was generated using serial 
10-fold dilutions of Namalwa Burkitt lymphoma cell line DNA (at two copies of EBV 
genome per cell) varying from 50,000 copies to 0.5 copies of EBV DNA per reaction. This 
curve was acceptable if sensitivity was at least 50 copies of EBV DNA per PCR, a 
difference of 3.3 +/- 0.3 cycles was demonstrated between each of the 10-fold dilutions, and 
if the correlation coefficient was at least 0.99. To check for amplicon contamination, every 
run contained at least two “no template” controls in which nuclease-free H2O was 
substituted for template.
All experimental samples were run in duplicate and a mean viral load was calculated based 
on the ratio of the copies of EBV to APOB in a given volume of extracted DNA, with APOB 
quantity representing the number of cells in the reaction. The resulting ratio was adjusted to 
provide the number of copies of EBV DNA per 100,000 cells. Samples with no measurable 
EBV DNA were reported as having a viral load of zero.
EBV-encoded RNA (EBER) in situ hybridization
EBER in situ hybridization was performed on paraffin sections of cases having detectable 
EBV DNA by at least one Q-PCR assay (n=86). This was accomplished using either a 
manual method with fluorescein-labeled oligonulceotide EBER and oligo(d)T control probes 
and the Super-Sensitive Poly-HRP ISH Non-Biotin Detection Kit (Biogenex, San Ramon, 
CA) with methyl green counterstain, or by an automated method using fluorescein-labeled 
EBER and oligo(d)T control probes on the Ventana Benchmark in situ hybridization system 
(Ventana Medical Systems, Tuscon AZ). Validation work on 56 samples showed no 
discrepancies between the two staining procedures. The oligo(d)T probe served as a control 
for RNA preservation in histological sections. A tumor was considered EBER-negative if 
EBER staining was undetected or was only expressed in benign-appearing lymphoid cells, 
and EBER-positive if the signal was localized to malignant epithelial cells.
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Immunohistochemistry for viral LMP1, LMP2, BMRF1, and BZLF1
Immunohistochemical stains for viral protein were performed on the 86 gastric cancer 
samples having detectable EBV DNA by Q-PCR. Stains for EBV LMP1 and LMP2 proteins 
were done as previously described(37) using citrate retrieval and the CS1-4 cocktail of 
mouse monoclonal antibodies against LMP1 (1:100, Dako, Capinteria, CA) and the E411 rat 
monoclonal antibody against LMP2A (1mg/ml, Asencion, Munich, Germany). Paraffin 
sections of EBV-related Hodgkin lymphoma served as positive controls.
Immunohistochemical analysis of the EBV replicative proteins BMRF1 and BZLF1 was 
performed using anti-BMRF1 clone G3-E31 (1:200 dilution, Research Diagnostics, Inc., 
Flanders, NJ) and anti-BZLF1 clone BZ.1 (1:25 dilution, Dako, Carpinteria, CA) on paraffin 
sections pretreated with citrate for antigen retrieval. Sections were incubated with primary 
antibody for 30 minutes at 37°C using the manufacturer’s blocking and detection protocols 
in the Super-Sensitive Non Biotin HRP Detection Kit (Biogenex). Bound antibody was 
detected by diaminobenzidine chromogen (Biogenex) and tissues were counter-stained with 
hematoxylin (Dako). Oral hairy leukoplakia paraffin sections served as a positive control.
Qualitative LMP2 PCR and DNA Sequencing
To further investigate a case in which the EBV LMP2 segment selectively failed to amplify 
by Q-PCR, a primer set was designed to amplify a 130bp region of the LMP2 gene 
encompassing the 69bp segment that had been targeted by the standard LMP2 Q-PCR assay. 
The following PCR primers were used: LMP2Ext forward 5′-
CTGTTTTGCAGCTGAGTCC-3′ and LMP2Ext reverse 5′-
CAATGTTAAAAGGGCTGCACC-3′. The 50μl reaction consisted of: 1X PCR Buffer, 
2mM MgCl2 2.5 units Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA), 0.2mM 
dNTPs (Applied Biosystems), 50ρmol of each LMP2Ext primer, and nuclease-free water. 
Reaction conditions were: 95°C for 2 minutes; 35 cycles of 95°C for 30 seconds, 60°C for 
30 seconds, and 72°C for 1 minute; and then 72°C for 10 minutes. The product was 
confirmed by electrophoresis in a 2% agarose gel containing 0.5mg/ml ethidium bromide. 
The product was sequenced in both directions by first removing unincorporated primers and 
dNTPs, and then incubating with shrimp alkaline phosphatase and exonuclease I 
(Amersham, Piscataway, NJ) at 37°C for 30 minutes, then 80°C for 15 minutes. The 12.5μl 
sequencing reaction consisted of: 1.1μl of template, 1μl LMP2Ext forward primer (5ρmol/
ml), 5μl BD Terminator Dye (Applied Biosystems), and water. The reaction was performed 
on the ABI 9700 thermocycler under the following conditions: 96°C for 5 seconds; 25 
cycles of 96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes; 60°C for 10 minutes 
followed by a hold at 4°C. The product was purified using the Qiagen DyeEx 2.0 Spin Kit, 
denatured at 95°C for 3 minutes, and separated by size in POP6 polymer by capillary 
electrophoresis on an ABI 3100 Gene Analyzer instrument. The sequence was compared to 
consensus EBV reference sequence in GenBank (NC_007605) and to wild type viral DNA 
from an EBER-positive AIDS lymphoma and another gastric carcinoma that were tested in 
parallel.
Ryan et al. Page 5















Gastric adenocarcinomas from the United States (n=75) and Central America (n=38) were 
classified by histopathology into intestinal pattern (n=50), diffuse pattern (n=55), or mixed 
pattern of tumor growth (n=8). The anatomic site of origin was classified as distal (n=93) for 
tumors occurring in the antrum or body, proximal (n=14) for tumors occurring in the cardia, 
or whole stomach (n=6). H. pylori infection was detected in 33/38 (87%) Central American 
gastric cancer patients by standard serological testing.
EBV DNA Measurement by Quantitative Real-Time PCR
Gastric adenocarcinoma tissues were screened for EBV genome using six separate Q-PCR 
assays targeting six different regions of the viral genome (BamH1W, EBNA1, LMP1, LMP2, 
BZLF1, and EBER1). Out of the 75 United States gastric cancers, 48 (64%) had detectable 
EBV DNA by at least one Q-PCR assay, and 11 (15%) were positive by all six Q-PCR 
assays (Table 1), while 27 (36%) were negative by all six assays. The Central American 
cases more frequently contained EBV DNA: 38/38 (100%) by at least one Q-PCR assay, and 
11 (29%) by all six Q-PCR assays (Table 2).
Virologic correlates in gastric adenocarcinomas
EBER in situ hybridization is considered the gold standard assay for localizing latent EBV 
infection in lesional cells. EBER in situ hybridization revealed EBV within the malignant 
epithelial cells in 8/48 (17%) of the cancers from the United States and in 3/38 (8%) of the 
Central American cancers that had detectable EBV DNA by at least one Q-PCR. The EBER-
negative cancer tissues often harbored scattered EBER-positive lymphocytes, including 
17/40 (42%) United States and 12/35 (34%) Central American cancers. No EBER expression 
was seen in benign epithelial cells or stromal elements. In the malignant cells, EBER was 
either uniformly positive or uniformly negative, supporting that EBV infection may have 
occurred before malignant transformation and was transmitted to all daughter cells in the 
neoplastic clone.
Interestingly, the viral loads for gastric cancers with detectable EBV DNA could be split 
into two general categories: 1) viral load greater than 10,000 copies per 100,000 cells, or 2) 
viral load less than 2,000 copies per 100,000 cells. With two exceptions (discussed below), 
those viral loads consistently greater than 10,000 EBV DNA copies/100,000 cells (8 from 
the United States and 3 Central American) were all EBV-associated tumors as defined by 
EBER localization to the malignant epithelial cells, whereas those with low viral loads 
lacked EBER in the malignant cells. The viral loads in the EBER-positive gastric cancers 
were nearly 3,000 fold higher than in the EBER-negative cancers (mean = 162,986 versus 62 
EBV DNA copies/100,000 cells, respectively; p=0.003). A cutoff value of 2,000 EBV 
copies per 100,000 cells is a reasonable and conservative level beyond which EBV was 
always localized to the malignant cells. A cost-effective screening strategy would be to 
reserve EBER staining for cases having viral loads over 2000 EBV copies per 100,000 cells. 
Among the EBER-negative malignancies, the 29 cases having visible EBER-positive 
lymphocytes by in situ hybridization had significantly higher EBV loads than those lacking 
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visible EBER in lymphocytes (mean = 110 versus 30 EBV DNA copies/100,000 cells, 
respectively, by the BamH1W assay; p=0.02).
Association between EBV status and clinicopathologic findings
Surprisingly, EBV was more commonly detectable by Q-PCR in Central American than in 
United States gastric cancer tissues (p=0.0001). But EBV was not more commonly localized 
to the malignant epithelial cells in Central American compared with United States cancers 
(p=0.61). Statistical power was insufficient to examine subcategories, but trends showed that 
EBER-positivity was similarly frequent in the proximal tumors (1/10, 10%) compared to 
distal tumors (7/62, 11%), and it was slightly more common in stumps (2/12, 17%). In 
support of previous reports, EBER-positivity was significantly more common in diffuse 
compared to intestinal histology (p=0.01). However, when Q-PCR was used to identify the 
virus, detectable EBV DNA was not preferentially found in cancers with diffuse rather than 
intestinal histology (p=0.83).
All the Central American gastric cancers were located in non-cardia regions. Among US 
gastric cancers, EBER-positive cases were not preferentially localized in the cardia region of 
the stomach including cardia comprising a stump after prior surgery. Although our numbers 
were small: 3/8 EBER-positive cancers occurred in the antrum, 2/8 in the body, 1/8 were 
widespread, and 2/8 were stump cancers. A similar distribution of anatomical sites was 
observed for the 17 United States gastric cancers that expressed EBER only in lymphocytes, 
where 8/17 occurred in the body, 4/17 in the antrum, 3/17 in the cardia, 1/17 were 
widespread, and 1/17 was a stump cancer.
A negative correlation between EBER-positive cancer and H. pylori serologic status was 
observed in the Central American cases (p<0.0001). H. pylori status for the United States 
cases could not be evaluated because serological testing was not performed, and histologic 
visualization of H. pylori is not reliable in the setting of gastric cancer.
EBV latently infects gastric adenocarcinomas
Immunohistochemistry was performed on all gastric cancers having detectable EBV DNA 
by any of the Q-PCR assays to localize the viral infection and to further characterize it as 
latent or lytic based on the spectrum of expressed viral proteins. No lytic EBV infection was 
observed as signified by the absence of BMRF1 or BZLF1 replicative protein expression in 
the malignant cells or in reactive stromal tissue. The pattern of latent viral gene expression 
varied among the gastric cancers. Viral LMP2A staining was observed in 4/11 EBER-
positive cancers and all four were among the eight United States cases. When present, 
LMP2A was restricted to the cytoplasm of malignant epithelial cells and was expressed 
diffusely in 1 case and focally in up to 10% of malignant cells in 3 cases (Figure 1A). Viral 
LMP1 expression was seen in only 1/11 EBER-positive gastric cancers, Central American 
case #51. In that case, membranous/cytoplasmic LMP1 was diffusely expressed and 
restricted to the malignant epithelial cells (Figure 1B), and the cells did not coexpress 
LMP2. No staining for LMP1 or LMP2 was observed in EBER-negative gastric cancers, nor 
was either protein expressed in infiltrating lymphocytes or benign epithelial cells.
Ryan et al. Page 7













Taken together, our results show three different viral latency profiles for EBV-associated 
gastric cancer: The majority of the EBER-positive cancers (4/8 United States and 2/3 Central 
American) were EBER+/LMP1-/LMP2A-. Less frequently, the latency profiles EBER+/
LMP1-/LMP2A+ (4/8 United States) and EBER+/LMP1+/LMP2A-(1/3 Central American) 
were observed.
Viral genomic variation in an EBV-associated Central American Gastric Cancer
EBER-positive Central American gastric cancer #49 had selective dropout of amplifiable 
EBV DNA for the LMP2 locus whereas the viral loads were greater than 112,000 EBV 
DNA copies per 100,000 cells for the other five viral load assays (Table 2). 
Immunohistochemical analysis of this cancer revealed no LMP2A protein expression, 
however this is not necessarily a result of a viral genomic defect since most cancers in this 
series did not express LMP2A. Although the primers and probes were designed to target a 
highly conserved segment of the LMP2 gene, the selective non-amplification suggests either 
mutation or deletion interfering with primer/probe binding. To resolve this dilemma, 
amplification and sequencing was performed on the relevant LMP2 gene segment. A point 
mutation was found near the 5′ end of the reverse primer, only three bases in from where the 
polymerase initiates strand extension (Figure 2). This mutation involved a conversion from a 
cytosine to a thymine at position number 733 in the LMP2 gene sequence compared to the 
wild type sequence found in the positive control and in GenBank Accession No. 
NC_007605. Our findings suggest that the LMP2 733C>T mutation hinders annealing of the 
reverse primer, resulting in reduced amplicon production.
Viral genomic variation in an EBER-negative US Gastric Cancer
The other exceptional case was an EBER-negative US gastric cancer case #24 with a single 
high LMP1 Q-PCR result and no other evidence of the virus beyond rare EBER-positive 
lymphocytes by in situ hybridization. The high level of LMP1 DNA is consistent with the 
levels of seen in EBV-associated gastric cancer rather than the levels seen in background 
infection of bystander lymphocytes. Repeat testing on four occasions verified the unusual 
results.
Discussion
This study is the first to demonstrate that quantitative real-time DNA amplification 
technology is equivalent to EBER in situ hybridization for identifying cases of gastric cancer 
that are EBV-related. We further showed that targeting viral DNA or EBER RNA is superior 
to immunohistochemical detection of selected viral proteins since these proteins are not 
consistently expressed at visible levels. Furthermore, expression patterns of viral proteins 
differed among cases, but always revealed latent infection. Use of multiple Q-PCR assays 
revealed that polymorphisms (mutation or deletion) of the viral genome may be more 
frequent than previously recognized.
When a battery of six different Q-PCR assays was applied to determine if one or a 
combination of these assays could be used to screen for EBV-related cancer, most of the Q-
PCR assays were equally informative. A threshold could be set that clearly distinguished 
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EBER-positive from EBER-negative cancers regardless of whether EBER-positive 
infiltrating lymphocytes were seen. With the exception of two unusual cases discussed 
below, no EBER-negative cancer had a viral load over 1,629, and no EBER-positive cancer 
had a level below 10,558 EBV copies per 100,000 cells. A cutoff value of 2,000 copies per 
100,000 cells is suggested as a threshold above which an EBER stain should be done to 
insure that the EBV signal is localized to the malignant cells, and below which EBER is 
likely to be restricted to benign lymphocytes, assuming that the tumor is adequately 
represented in the sample. Note that this cutoff is substantially higher than the threshold of 
100 EBV copies per 100,000 cells that had been set in a prior study of non-gastric 
malignancies, including non-Hodgkin lymphomas.(37) This difference suggests that EBER-
negative gastric cancer tissues tend to have higher EBV loads than do EBER-negative 
lymphoma tissues, implicating higher levels of EBV in the non-malignant cells of the 
stomach.
Prior work localized EBV to benign lymphocytes in gastritis lesions and other preneoplastic 
gastric lesions.(14, 29, 39-43) In the current study, scattered EBER-positive lymphocytes 
were found in some EBER-negative cancer tissues where they tended to correlate with 
measurable viral loads. No other benign cell types were found to contain either latent or lytic 
viral infection by histochemical stains. Although we did not study preneoplastic tissue or 
lesions, it will be important to determine if patients who eventually develop cancer have 
higher levels of EBV beforehand. In this regard, it is worth considering if the high incidence 
of gastric cancer in Central America is related to the relatively high EBV loads seen in every 
gastric cancer from that region regardless of EBER status. Further studies are needed to 
explore whether host genetic, immunologic, infectious, or nutritional factors caused the 
levels of EBV to be higher in Central American compared to United States gastric cancer 
tissue.
The laboratory assays described in the current study were clearly useful for identifying 
infected cancers, and further work is needed to explore their utility for measuring low level 
EBV in preneoplastic tissue or in blood. Among the six assays that were used, the BamH1W 
assay had the lowest limit of detection, while the LMP1 and LMP2 assays were more likely 
to miss low-level infection as judged by the frequency of amplification in our EBER-
negative cancer tissues. For applications in which analytic sensitivity is critical, the 
BamH1W Q-PCR is recommended.
Our results build on prior work by others demonstrating that EBV is found in distinct 
clinicopathologic subtypes of gastric cancer, suggesting that the virus is not just an innocent 
bystander but rather it tracks with fundamental biologic and immunologic characteristics 
that are likely to influence tumor development and maintenance. Although the incidence of 
gastric cancer is much higher in Central America than in the United States, our work shows 
that the proportion of EBV-related cases (as defined by EBER expression in malignant cells) 
is not radically different between the two countries (8% versus 17%, respectively; p=0.23) 
and is comparable to rates described by others worldwide.(4, 5, 7, 11, 29, 32, 44, 45) The 
geographic variation is not as dramatic as with other EBV-related diseases such as Burkitt 
lymphoma in which EBV-positivity rates vary from over 95% in tropical Africa to 25% in 
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the United States, and nasopharyngeal carcinoma where rates vary from over 95% in 
Southern China to about 75% in the United States.(18)
A known contributing oncogenic factor is H. pylori infection. In fact, both EBV and H. 
pylori are considered class 1 oncogenic pathogens by the World Health Organization 
(WHO) and are associated with overlapping subsets of gastric carcinoma.(6, 46, 47) H. 
pylori is endemic among adults in Honduras, while the United States carrier rate is about 
30% among adults. Unless treated with medications to eradicate the bacterium, the majority 
of individuals maintain chronic infection. In our Central American cohort on whom 
serologic testing was performed, a significant negative association was found between 
EBER-positive cancer and H. pylori infection. Further studies are warranted to determine if 
different mechanisms of carcinogenesis are operative.
Because mutation or partial genomic deletion could interfere with detection of viral DNA or 
gene products, a battery of six Q-PCR assays was used to assay multiple segments of the 
viral genome. In any given tumor specimen, the viral loads were fairly consistent across the 
six Q-PCR assays and were clearly informative with regard to EBER in situ hybridization 
status, suggesting that one or more of these Q-PCR assays could be used as a screening tool 
for EBV-related cancer in paraffin-embedded tissue. It is important to note that one of the 
gastric cancers in this series would have yielded a false negative interpretation of EBV 
status if only the LMP2 Q-PCR assay had been used. In a prior study, false negative Q-PCR 
assays targeting either LMP2, LMP1, or BZLF1 were seen in AIDS lymphomas.(37) These 
findings demonstrate the importance of targeting more than one segment of the viral genome 
to ensure sensitive detection of the virus.
US gastric cancer case #24 was exceptional in that a high LMP1 Q-PCR value was found 
despite undetectable virus by the other five Q-PCRs. The high level of LMP1 DNA is 
consistent with the levels seen in EBV-associated gastric cancers, however the gold standard 
EBER in situ assay showed no EBER localization to malignant cells, and LMP1 
immunohistochemistry was likewise negative. While it is feasible that this LMP1 Q-PCR 
result is false positive (perhaps crossreacting with a rare pathogen), one must consider the 
possibility that the result legitimately reflects a segment of EBV DNA. Interestingly, the 
LMP1 gene is considered to be an oncogene in that it has many qualities that promote 
tumorigenesis. First, deletion of the LMP1 gene renders EBV incapable of immortalizing B 
cells.(48) Second, LMP1 functions as a TNF receptor that constitutively signals through 
multiple growth-promoting and anti-apoptotic pathways including EGFR, NFKB, PI3K and 
AKT.(49, 50) Its effect on the inhibitors of differentiation (ID1 and ID3) could help explain 
why infected carcinomas tend to appear so undifferentiated.(51) Transgenic mice expressing 
LMP1 behind a keratin promoter develop epithelial hyperplasia while LMP1 expressed 
behind an immunoglobulin promoter induces B cell lymphoma.(50) In this patient, it is 
feasible that a defective recombinant viral genome containing LMP1 could have been 
produced naturally by atypical rearrangement and partial deletion of the EBV genome. 
Integration of the defective LMP1-containing segment into host chromosomal DNA is a 
possible mechanism of persistence. The intact EBV genome may also persist in this patient 
as evidenced by rare EBER-expressing lymphocytes. If future work confirms that remnants 
of the EBV genome are indeed present within the malignant cells in cases such as this one, it 
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would lend support to the hit-and-run hypothesis by which EBV might have contributed 
early during tumorigenesis but then was largely eliminated from the epithelial cells prior to 
clonal expansion.
The current study demonstrates that latent, not lytic, EBV infection characterizes gastric 
adenocarcinomas. This confirms previous reports showing that virally encoded EBER and 
LMP2 are often expressed, but LMP1 is very rarely expressed.(29, 30, 32, 52-56) EBER, a 
non-polyadenylated transcript, is thought to promote growth of gastric epithelial cells at 
least in part through induction of insulin-like growth factor (IGF1).(57) Only one case in the 
current series expressed LMP1 by histochemical analysis, while 4/11 infected cases 
expressed LMP2A. It is important to characterize viral gene expression not only because 
viral gene products serve as targets to assist in laboratory diagnosis, but also because they 
may serve as targets for therapy. The immune system seems to tolerate latent viral infection 
in this and other infected malignancies.(58) Some progress has been made in managing 
EBV-related cancers by infusing cytotoxic T cells which have been expanded in vitro 
through stimulation by viral proteins.(59) Another promising strategy is to use 
differentiating agents that induce lytic viral replication, which incites a strong antiviral 
immune reaction.(60-62)
Prior research showed lytic EBV infection in some gastric adenocarcinomas using either 
histochemistry or rtPCR.(29, 32) In the current study, lytic viral protein expression was not 
detected by either BZLF1 or BMRF1 immunohistochemistry, suggesting that cells 
undergoing replicative infection are rare. These findings are relevant to patient care since 
one would predict that well-tolerated oral antiviral agents like gancyclovir, which target 
replicative infection, are unlikely to eliminate malignant cells. Nevertheless, even rare cells 
expressing lytic viral proteins may contribute to angiogenesis and tumor growth.(63) In fact, 
Kenney and colleagues succeeded in killing malignant cells using gancyclovir combined 
with standard chemotherapeutic or radiation therapies, presumably because gancyclovir is 
activated by phosphorylation in cells that the standard therapies induce to switch from 
latency to lytic viral replication.(64-66) Not only are the lytically infected cells killed, but 
adjacent cells die as phosphorylated gancyclovir is transferred to them and exerts its 
cytotoxic activity.(64) Once EBV-directed therapies are established to be useful in patient 
management, it will be all the more important to identify virally-infected cancers that would 
be predicted to respond to the therapy. Meantime, the utility of knowing that a particular 
patient’s cancer is EBV-infected may be limited to prognosis(7, 67) and to measurement of 
circulating EBV DNA as a marker of tumor burden.(68) The laboratory assays described 
herein should prove useful for identifying affected patients.
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Figure 1. Latent viral protein expression in gastric adenocarcinomas
A) Hematoxylin and eosin stain reveals gastric adenocarcinoma in United States Case #6. B) 
Immunohistochemistry shows LMP2A expression localized to the malignant cells of United 
States Case #6. C) Immunohistochemistry reveals LMP1 is expressed in the malignant cells 
of Central American Case #51. (A, B 400×; C 100×)
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Figure 2. EBV LMP2 DNA sequencing revealed a mutation interfering with primer binding
DNA sequencing was performed on a 130bp region of EBV LMP2 encompassing the 69bp 
region targeted by the LMP2 Q-PCR assay. The forward and reverse primer binding sites for 
the LMP2 Q-PCR assay are in bold font, while the TaqMan probe site is underlined. The star 
represents the position of a point mutation (C>T base substitution at position 733) in LMP2 
exon 4 of Central American Case #49, which is predicted to result in substitution of serine 
by phenylalanine; this substitution of a large nonpolar for a small polar amino acid may have 
functional significance in addition to its apparent interference with laboratory testing.
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